Rasna Therapeutics, Inc.

Common Stock SEC Reporting - Current
Contact Info
  • 420 Lexington Avenue
  • Suite 2525
  • New York, NY 10170

Business Description

Update Company Profile
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jun 30, 2017 10-Q
CIK 0001582249
Fiscal Year End 9/29
OTC Marketplace OTCQX U.S.
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: NV, USA
Year of Inc. 2012
Employees 8 a/o Mar 13, 2017
Company Officers/Contacts
Kunwar Shailubhai CEO
Tiziano Lazzaretti CFO
Company Directors
Alessandro Padova Chairman, Independent Director
John P. Brancaccio Independent Director, Audit Committee Member
Riccardo Dalla-Favera Independent Director, Compensation Committee Member
John Alex Martin Independent Director
Jim Mervis Independent Director, Audit Committee Member
Kunwar Shailubhai Independent Director, Compensation Committee Member
Service Providers
Accounting/Auditing Firm
Marcum LLP
53 State Street, 38th Floor
Boston, MA, 02109
United States
Securities Counsel
Sheppard, Mullin, Richter & Hampton LLP OTCQX Sponsor
30 Rockefeller Plaza
New York, NY, 10112-0015
United States
Investor Relations Firm

Not Available
Company History
  • Formerly=Active With Me Inc. until 9-2016
RASP Security Details
Share Structure
Market Value1 $172,270,008 a/o Dec 08, 2017
Authorized Shares 200,000,000 a/o Sep 29, 2016
Outstanding Shares 68,908,003 a/o Nov 29, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 5,866,254 a/o Sep 29, 2016
Par Value 0.001
Transfer Agent(s) Verified by Transfer Agent
Philadelphia Stock Transfer, Inc.
Shareholders of Record 65 a/o Nov 30, 2017
Short Selling Data
Short Interest 300 (0%)
Nov 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security